title: Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy.
abstract: OBJECTIVE
  To assess the effectiveness of prophylactic albumin for the prevention of ifosfamide-induced encephalopathy (IIE), and to describe risk factors for IIE and investigate the predictive potential of a novel risk-stratification model for IIE.
  
  
  METHODS
  Retrospective analysis.
  
  
  METHODS
  Single academic medical center.
  
  
  METHODS
  Forty-one adults who received 93 chemotherapy cycles of regimens that included ifosfamide for the treatment of hematologic or solid tumor malignancy between November 2007 and November 2008. Patients were divided into two groups based on the use of albumin for IIE prophylaxis: albumin group (32 cycles) and no albumin group (61 cycles).
  
  
  RESULTS
  Overall occurrence of neurotoxicity during therapy served as the primary outcome measure. Proposed risk factors for IIE were assessed by conducting a subgroup analysis of patients who did and those who did not experience IIE. A novel risk-stratification model was developed in an attempt to predict patients at risk for IIE. The validity of the scheme was assessed by comparing the occurrence of IIE among high- and low-risk patients as identified by the model. Overall, among the 93 cycles, six cases of IIE (6.5%) were identified. The occurrence of IIE was more common in the albumin group compared with the no albumin group (15.6% [5/32] vs 1.6% [1/61], p=0.01). Baseline albumin level was significantly lower, and serum creatinine and aspartate and alanine aminotransferase concentrations were significantly higher among patients experiencing IIE. All cases of IIE occurred among patients identified as high risk according to the risk-stratification model (p=0.01).
  
  
  CONCLUSIONS
  Prophylactic therapy with exogenous albumin is not an effective strategy for the prevention of IIE. The novel risk-stratification model appears to be an effective method for predicting patients with the greatest potential for developing this adverse effect.
authors.affiliation: Department of Pharmacy, University of Kansas Hospital, Kansas City, KS 66160, USA.
authors.forename: Jacob K
authors.initials: JK
authors.lastname: Kettle
authors.forename: Dennis
authors.initials: D
authors.lastname: Grauer
authors.forename: Tanya L
authors.initials: TL
authors.lastname: Folker
authors.forename: Nyla
authors.initials: N
authors.lastname: O'Neal
authors.forename: David W
authors.initials: DW
authors.lastname: Henry
authors.forename: Casey B
authors.initials: CB
authors.lastname: Williams
mesh_terms: D000046:Academic Medical Centers / Q000379:methods; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D034141:Hypoalbuminemia / Q000150:complications / Q000188:drug therapy; D007069:Ifosfamide / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D020258:Neurotoxicity Syndromes / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control*; D012189:Retrospective Studies; D012307:Risk Factors; D012709:Serum Albumin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D012709:Serum Albumin; D007069:Ifosfamide